Feature | January 14, 2013

Oslo Breast Cancer Screening Trial Concludes Use of 3-D With 2-D Exam Finds Significantly More Cancers

Hologic Inc. Radiology RSNA 3-D Mammography Clinical Study

January 14, 2013 — Hologic Inc. announced that a groundbreaking new clinical study published in Radiology, the Radiological Society of North America scientific journal, found that the addition of three dimensional (3-D) mammography (breast tomosynthesis) screening technology to a 2-D breast screening exam significantly increased cancer detection while reducing the number of false positives.

The study, "Comparison of Digital Mammography Alone and Digital Mammography plus Tomosynthesis in a Population-based Screening Program," was led by Per Skaane, M.D., Ph.D. of Oslo University Hospital Ullevaal. The study was based on 12,631 screening examinations in a large hospital in Norway.

The researchers using Hologic's 3-D mammography technology in combination with a 2-D mammogram found a significant increase in cancer detection rates, particularly for invasive cancers, and a simultaneous decrease in false-positive rates compared with 2-D mammography alone. Significant findings include:

  • A 40 percent increase in the detection of invasive breast cancers
  • A 27 percent increase in the detection of all cancers (invasive and in situ cancers combined)
  • A 15 percent decrease in false-positive rates

The authors reported that the increase in cancer detection was found across all breast tissue densities, from dense to fatty. At the same time, there was no increase in the detection of ductal carcinoma in situ (DCIS), which is non-invasive and cited by critics of mammography screening as potentially being over-diagnosed.

As a result of the large increase in the detection of invasive cancers rather than in situ cancers the authors of the paper state, "Perhaps our most important observation is that with the mammography-plus-tomosynthesis arm, the actual benefit, in terms of possibly improving outcome owing to earlier detection, may be larger than merely the difference in the total count or number of detected cancers."

Rob Cascella, Hologic's president and chief executive iofficer said, "A number of major papers demonstrating the value of 3-D mammography have been published in the last few months. The Oslo trial is the first large-scale prospective study to show the additional cancers found with 3-D mammography in combination with 2-D mammography were invasive cancers — the very type of cancers we want to detect and treat early. Three-dimensional mammography is the best breast screening technology to date in that it finds significantly more invasive cancers while also reducing false positives. Most other imaging technologies for screening require users to compromise specificity (recall rate) for sensitivity (cancer detection). We believe the value of 3-D mammography in breast cancer screening is most compelling."

Three-dimensional mammography was approved for clinical use for breast cancer screening and diagnosis in the United States in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic's 3-D mammography technology is in use in 47 states and 30 countries outside the United States. Unlike a screening 2-D digital mammogram, which involves a single X-ray image of the breast, 3-D mammography captures multiple, low-dose images from multiple angles around the breast. The images are then used to produce a 3-D reconstruction of the breast.

Skaane and his research team in Oslo are well known for their research. Their Oslo I and Oslo II trials were important studies comparing 2-D digital mammography to screen-film for the detection of breast cancer.

The study was published online in advance of print on the Radiology website.

For more information: www.hologic.com/investors-overview

Related Content

Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
An example of opto-acoustic breast imaging using the Seno system.

An example of opto-acoustic breast imaging using the Seno system.  

Feature | RSNA 2017 | January 29, 2018
January 26, 2017 — There were three high-impact clinical trials presented at the 2017 Radiological Society of North A
What It Takes to Remain an MQSA-Qualified Inspector
Feature | Mammography | January 26, 2018
The U.S. Food and Drug Administration (FDA) published a new Insight Article detailing the oversight process for the...
Advaxis Immunotherapy Offers Potential Combo Treatment for Anal Cancer
News | Radiation Therapy | January 26, 2018
January 26, 2018 — Advaxis Inc.
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
Overlay Init